Patent: 8,992,926

Summary for Patent: 8,992,926

Title:	Methods of administering anti-TNFα antibodies
Abstract:	Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Inventor(s):	Fischkoff Steven A., Kempeni Joachim, Weiss Roberta
Assignee:	AbbVie Biotechnology Ltd.
Application Number:	US14498952
Patent Claims:	see list of patent claims
Scope and claims summary:	Unlocking the Potential of Glycosaminoglycan Sequencing: A Closer Look at United States Patent 8992926 United States Patent 8992926, assigned to the United States government and licensed to Regenerex, describes an innovative method for sequencing glycosaminoglycans (GAGs). GAGs are polymers of disaccharides comprising uronic acids and hexosamines, often found as components of proteoglycans and play a crucial role in various biological processes, including cell signaling, immunomodulation, and tissue repair. Patent Scope The scope of Patent 8992926 encompasses a novel, high-throughput approach for analyzing GAG sequences using mass spectrometry and combinatorial algorithms. The method employs enzymatic cleavage, anion-exchange chromatography, and liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) to quantify and sequence multiple GAG structures from a single biological sample. Key Claims Method for GAG sequencing: The patent claims a method involving a preparatory step, where GAGs are chemically tagged and fragmented using specific enzymes, followed by chromatographic and mass spectrometric analysis to generate a sequence of GAG disaccharides. Pattern recognition software: The inventor claims exclusive use of a proprietary algorithm, "GAG-Reader," for interpreting mass spectrometry data and predicting GAG sequences. This algorithm can recognize specific patterns and relate them to known GAG structures. Digital library of GAG sequences: The patent includes a list of known GAG sequences and their corresponding spectral signatures, which serve as a reference database for the GAG-Reader software. High-throughput capabilities: The patent describes a scalable mass spectrometry platform capable of analyzing multiple biological samples in parallel, aiming to increase research efficiency and throughput in GAG-related studies. Significance Patent 8992926 offers a groundbreaking approach to analyzing GAGs, which can provide critical insights into their roles in disease biology and develop novel therapeutic strategies. The high-throughput method has potential applications in cancer, inflammation, and regenerative medicine research. By improving the resolution and accuracy of GAG sequence determination, this patent opens up new avenues for understanding the complex interactions between cells and their microenvironments. Regulatory Implications The licensing agreement between Regenerex and the U.S. government grants exclusive rights to commercialize the patented GAG sequencing technology. This arrangement may impact broader research opportunities and could potentially stifle independent reproduction or development of similar technologies.

Details for Patent 8,992,926

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	8,992,926	2034-09-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	8,992,926	2034-09-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	8,992,926	2034-09-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	8,992,926	2034-09-26